Aehr Test Systems (AEHR): We Called the $60M Stock Raise — Here's What Investors Need to Know Now

We've been following Aehr Test Systems since late 2022. We watched it run from a micro-cap to a $3 billion market cap on the back of AI accelerator hype — and we called what was coming next.In this episode, Nick walks through the full picture on Aehr Test Systems (AEHR): what the business actually does today, why the valuation has dramatically outpaced the fundamentals, and why management issuing $60 million worth of new stock into the market is exactly the signal investors needed to see.The core tension is straightforward but important. Aehr's InCal acquisition was genuinely smart — it diversified the business away from pure silicon carbide and EV testing into AI accelerator burn-in, likely serving Google's TPU supply chain through a subcontractor. Growth is returning. But the stock already reflects a massive, multi-year recovery in a single move. With quarterly revenue of just $10 million and fiscal 2027 guidance that implies somewhere between $50–100 million in annual revenue, a $2.5–3 billion market cap is pricing in a lot of optimism that hasn't been earned yet.This is a pattern CSI has seen before with Aehr — almost identically in mid-2023 during the silicon carbide and EV cycle peak. The key difference this time is that AI data center demand is likely more durable than EV was. But that doesn't mean the stock can't get ahead of itself in the meantime.The $60M ATM raise is management's way of saying: we agree the stock is ahead of our near-term guidance, and we're going to take advantage of that. It's not a death knell for the company. It is a clear signal about where we are in the cycle.What we cover:— Aehr's business today: silicon carbide, AI accelerator testing, and the InCal acquisition— Why $10M/quarter in revenue doesn't support a $3B market cap — yet— The ATM stock offering explained: what it is and why management used it— How the 2026 setup compares to the 2023 silicon carbide cycle top— Fiscal 2027: what management has guided and what remains unknown— Where the risk/reward sits for new investors considering entry nowSponsored by fiscal.ai — the platform Nick and Kasey use daily for semiconductor research. Get 15% off any paid plan at fiscal.ai/csiDisclosure: Nick and Kasey have held positions in Aehr Test Systems. This content is for general information only and is not individual investment advice. All investing involves risk.chipstockinvestor.com